

Edgar Filing: Altus Pharmaceuticals Inc. - Form SC 13G

Altus Pharmaceuticals Inc.
Form SC 13G
July 20, 2007

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G
(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b), (c)
AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No.)*

Altus Pharmaceuticals Inc.
(Name of Issuer)

Common Stock, \$.01 par value
(Title of Class of Securities)

02216N105
(CUSIP Number)

July 10, 2007
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:

- Rule 13d-1(b)
 Rule 13d-1(c)
 Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).

Schedule 13 G
CUSIP No. 02216N105

PAGE 2 OF 11

(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Edgar Filing: Altus Pharmaceuticals Inc. - Form SC 13G

OZ Management LP

(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) []
(b) [x]

(3) SEC USE ONLY

(4) CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF (5) SOLE VOTING POWER
SHARES 1,762,798

BENEFICIALLY (6) SHARED VOTING POWER
OWNED BY 0

EACH (7) SOLE DISPOSITIVE POWER
REPORTING 1,762,798

PERSON WITH (8) SHARED DISPOSITIVE POWER
0

(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
1,762,798

(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES []

(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
5.8%

(12) TYPE OF REPORTING PERSON
IA

Schedule 13 G
CUSIP No. 02216N105

PAGE 3 OF 11

(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
OCH-ZIFF GP LLC

(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) []
(b) [x]

(3) SEC USE ONLY

Edgar Filing: Altus Pharmaceuticals Inc. - Form SC 13G

(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware

NUMBER OF (5) SOLE VOTING POWER
SHARES 1,762,798

BENEFICIALLY (6) SHARED VOTING POWER
OWNED BY 0

EACH (7) SOLE DISPOSITIVE POWER
REPORTING 1,762,798

PERSON WITH (8) SHARED DISPOSITIVE POWER
0

(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
1,762,798

(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES []

(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
5.8%

(12) TYPE OF REPORTING PERSON
OO

Schedule 13 G
CUSIP No. 02216N105

PAGE 4 OF 11

(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Daniel S. Och

(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) []
(b) [x]

(3) SEC USE ONLY

(4) CITIZENSHIP OR PLACE OF ORGANIZATION
United States

NUMBER OF (5) SOLE VOTING POWER
SHARES 1,762,798

Edgar Filing: Altus Pharmaceuticals Inc. - Form SC 13G

BENEFICIALLY (6) SHARED VOTING POWER
OWNED BY 0

EACH (7) SOLE DISPOSITIVE POWER
REPORTING 1,762,798

PERSON WITH (8) SHARED DISPOSITIVE POWER
0

(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
1,762,798

(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES []

(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
5.8%

(12) TYPE OF REPORTING PERSON
IN

Schedule 13 G
CUSIP No. 02216N105

PAGE 5 OF 11

(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Oz Master Fund, Ltd.

(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) []
(b) [x]

(3) SEC USE ONLY

(4) CITIZENSHIP OR PLACE OF ORGANIZATION
United States

NUMBER OF (5) SOLE VOTING POWER
SHARES 1,684,920

BENEFICIALLY (6) SHARED VOTING POWER
OWNED BY 0

EACH (7) SOLE DISPOSITIVE POWER

Edgar Filing: Altus Pharmaceuticals Inc. - Form SC 13G

1,684,920

REPORTING -----

PERSON WITH (8) SHARED DISPOSITIVE POWER
0

(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
1,684,920

(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES []

(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
5.5%

(12) TYPE OF REPORTING PERSON
CO

Schedule 13 G
CUSIP No. 02216N105

PAGE 6 OF 11

ITEM 1(a). NAME OF ISSUER:
Altus Pharmaceuticals Inc.

ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
125 Sidney Street, Cambridge, MA 02139

ITEMS 2(a), 2(b) and 2(c). NAME OF PERSON FILING, ADDRESS OF PRINCIPAL
BUSINESS OFFICE AND CITIZENSHIP:

This statement is filed by the entities and persons listed below, all of
whom together are referred to herein as the "Reporting Persons":

- (i) OZ Management LP ("OZ"), a Delaware limited partnership,
with respect to the Shares reported in this Schedule 13G held by
certain investment funds and discretionary accounts managed
by OZ (the "Accounts").
- (ii) Och-Ziff GP LLC ("OZGP"), a Delaware limited liability company
which serves as the general partner of OZ, with respect to the
Shares reported in this Schedule 13G held by the Accounts.
- (iii) Daniel S. Och, who is the Senior Managing Member of OZGP, with
respect to the Shares reported in this Schedule 13G managed
by OZ and held by the Accounts.
- (iv) Oz Master Fund, Ltd. ("OZMD"), a Cayman Islands company, with
respect to shares owned by it.

The citizenship of OZ, OZGP and OZMD is set forth above. Daniel S.
Och is a United States citizen.

The address of the principal business office of each of the Reporting

Edgar Filing: Altus Pharmaceuticals Inc. - Form SC 13G

Persons except OZMD is 9 West 57th Street, 39th Floor, New York, NY 10019. The address of the principal business office of OZMD is c/o Goldman Sachs (Cayman) Trust, Limited, P.O. Box 896, G.T. Harbour Centre, Second Floor, North Church Street, George Town, Grand Cayman, Cayman Islands.

Schedule 13 G
CUSIP No. 02216N105

PAGE 7 OF 11

ITEM 2(d). TITLE OF CLASS OF SECURITIES:
Common Stock, \$.01 par value.

ITEM 2(e). CUSIP NUMBER: 02216N105

ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

- (a) Broker or dealer registered under Section 15 of the Act;
- (b) Bank as defined in Section 3(a)(6) of the Act;
- (c) Insurance Company as defined in Section 3(a)(19) of the Act;
- (d) Investment Company registered under Section 8 of the Investment Company Act of 1940;
- (e) Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940: see Rule 13d-1(b)(1)(ii)(E);
- (f) Employee Benefit Plan, Pension Fund which is subject to the provisions of the Employee Retirement Income Security Act of 1974 or Endowment Fund; see Rule 13d-1(b)(1)(ii)(F);
- (g) Parent Holding Company, in accordance with Rule 13d-1(b)(ii)(G);
- (h) Savings Associations as defined in Section 3(b) of the Federal Deposit Insurance Act;
- (i) Church Plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940;
- (j) Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

IF THIS STATEMENT IS FILED PURSUANT TO Rule 13d-1(c), CHECK THIS BOX.

Edgar Filing: Altus Pharmaceuticals Inc. - Form SC 13G

Schedule 13 G
CUSIP No. 02216N105

PAGE 8 OF 11

ITEM 4. OWNERSHIP.

OZ serves as principal investment manager to a number of investment funds and discretionary accounts with respect to which it has voting and dispositive authority over the Shares reported in this Schedule 13G, including such an account for OZMD. OZGP serves as the general partner of OZ. As such, it may be deemed to control OZ and therefore may be deemed to be the beneficial owner of the Shares reported in this Schedule 13G. Mr. Daniel S. Och is the Senior Managing Member of OZGP. As such, he may be deemed to control such entity and therefore may be deemed to be the beneficial owner of the Shares reported in this Schedule 13G.

Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares.

A. OZ

(a) Amount beneficially owned: 1,762,798

(b) Percent of class: 5.8%

(All percentages herein are based on 30,584,769 shares of Common Stock reported to be outstanding as of April 30, 2007, as reflected in the Form 10-Q filed by the Company on May 10, 2007.)

(c) Number of shares as to which such person has:

(i) sole power to vote or to direct the vote
1,762,798

(ii) shared power to vote or to direct the vote 0

(iii) sole power to dispose or to direct the disposition of
1,762,798

(iv) shared power to dispose or to direct the disposition of
0

B. OZGP

(a) Amount beneficially owned: 1,762,798

(b) Percent of class: 5.8%

(c) Number of shares as to which such person has:

(i) sole power to vote or to direct the vote 1,762,798

(ii) shared power to vote or to direct the vote 0

(iii) sole power to dispose or to direct the disposition of
1,762,798

(iv) shared power to dispose or to direct the disposition of
0

C. Daniel S. Och

(a) Amount beneficially owned: 1,762,798

(b) Percent of class: 5.8%

(c) Number of shares as to which such person has:

(i) sole power to vote or to direct the vote 1,762,798

(ii) shared power to vote or to direct the vote 0

Schedule 13 G
CUSIP No. 02216N105

PAGE 9 OF 11

(iii) sole power to dispose or to direct the disposition of
1,762,798

Edgar Filing: Altus Pharmaceuticals Inc. - Form SC 13G

- (iv) shared power to dispose or to direct the disposition of 0

D. OZMD

- (a) Amount beneficially owned: 1,684,920
- (b) Percent of class: 5.5%
- (c) Number of shares as to which such person has:
 - (i) sole power to vote or to direct the vote 1,684,920
 - (ii) shared power to vote or to direct the vote 0
 - (iii) sole power to dispose or to direct the disposition of 1,684,920
 - (iv) shared power to dispose or to direct the disposition of 0

ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
Not applicable.

ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
See Item 4.

ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY. Not applicable.

ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
See Item 4.

ITEM 9. NOTICE OF DISSOLUTION OF GROUP.
Not applicable.

ITEM 10. CERTIFICATION. (if filing pursuant to Rule 13d-1(c))

Each of the Reporting Persons hereby make the following certification:

By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and not held in connection with or as a participant in any transaction having that purpose or effect.

Schedule 13 G
CUSIP No. 02216N105

PAGE 10 OF 11

SIGNATURES

After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

DATED: July 20, 2007

/s/ Daniel S. Och

OZ MANAGEMENT LP
By Och-Ziff GP LLC

Edgar Filing: Altus Pharmaceuticals Inc. - Form SC 13G

its general partner
By Daniel S. Och
Senior Managing Member

/s/ Daniel S. Och

OCH-ZIFF GP LLC
By Daniel S. Och
Senior Managing Member

/s/ Daniel S. Och

Daniel S. Och

/s/ Daniel S. Och

OZ MASTER FUND, LTD.
By Daniel S. Och
Director

CUSIP No. 02216N105

13 G

PAGE 11 OF 11

EXHIBIT 1

JOINT ACQUISITION STATEMENT
PURSUANT TO RULE 13d-1(k)

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

DATED: July 20, 2007

/s/ Daniel S. Och

OZ MANAGEMENT LP
By Och-Ziff GP LLC
its general partner
By Daniel S. Och
Senior Managing Member

/s/ Daniel S. Och

OCH-ZIFF GP LLC
By Daniel S. Och
Senior Managing Member

Edgar Filing: Altus Pharmaceuticals Inc. - Form SC 13G

/s/ Daniel S. Och

Daniel S. Och

/s/ Daniel S. Och

OZ MASTER FUND, LTD.
By Daniel S. Och
Director